Literature DB >> 17009920

Impaired regulation of immune responses in cognitive decline and Alzheimer's disease: lessons from genetic association studies.

Martina Chiappelli1, Emanuela Tumini, Elisa Porcellini, Federico Licastro.   

Abstract

Altered levels of cytokines and acute-phase proteins have been described in the blood and brain of patients with Alzheimer's disease. Microglia are resident cells of the brain and metabolic upregulation of these cells may play a crucial role in the development of the neurodegeneration associated with Alzheimer's disease. Studies focusing on gene polymorphisms of molecules with immune regulatory function have demonstrated an association with increased risk of the disease and confirmed the pivotal role of immune responses in Alzheimer's disease pathogenesis. Several gene variants may also influence the rate of the cognitive decline associated with the disease. A definite immune-related gene polymorphism profile may be a feature of a limited group of patients with early onset of the disease and fast clinical deterioration. Only this group of patients may benefit from anti-inflammatory treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17009920     DOI: 10.1586/14737175.6.9.1327

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  3 in total

1.  Pathophysiology of age-related diseases.

Authors:  Giuseppina Campisi; Martina Chiappelli; Massimo De Martinis; Vito Franco; Lia Ginaldi; Rosario Guiglia; Federico Licastro; Domenico Lio
Journal:  Immun Ageing       Date:  2009-09-08       Impact factor: 6.400

2.  Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease.

Authors:  Zuzana Stozicka; Norbert Zilka; Petr Novak; Branislav Kovacech; Ondrej Bugos; Michal Novak
Journal:  J Neuroinflammation       Date:  2010-10-12       Impact factor: 8.322

3.  Altered glycosylation profile of purified plasma ACT from Alzheimer's disease.

Authors:  Manuela Ianni; Marcella Manerba; Giuseppina Di Stefano; Elisa Porcellini; Martina Chiappelli; Ilaria Carbone; Federico Licastro
Journal:  Immun Ageing       Date:  2010-12-16       Impact factor: 6.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.